{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:08:50Z","timestamp":1768514930124,"version":"3.49.0"},"posted":{"date-parts":[[2024,8,16]]},"group-title":"Molecular Biology","reference-count":57,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Coronary artery disease (CAD) is the leading cause of death worldwide. It imposes an enormous symptomatic burden on patients, leaving many with residual disease despite optimal procedural therapy, and up to 1\/3 with debilitating angina amenable neither to procedures, nor to current pharmacologic options. Semaglutide, a glucagon-like peptide 1 agonist originally approved for management of diabetes, has garnered substantial attention for its capacity to attenuate cardiovascular risk. Although subgroup analyses in patients indicate promise, studies explicitly designed to isolate the impact of semaglutide on the sequelae of CAD, independently of comorbid diabetes or obesity, are lacking.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Approach and Results<\/jats:title>\n                  <jats:p>Yorkshire swine (n=17) underwent placement of an ameroid constrictor around the left circumflex coronary artery to induce CAD. Oral semaglutide was initiated postoperatively at 1.5 mg and scaled up in 2 weeks to 3 mg in treatment animals (SEM, n=8) for a total of 5 weeks, while control animals (CON, n=9) received no drug. All then underwent myocardial harvest with acquisition of perfusion and functional data using microsphere injection and pressure-volume loop catheterization. Immunoblotting, immunohistochemistry, and immunofluorescence were performed on the most ischemic myocardial segments for mechanistic elucidation. SEM animals exhibited improved left ventricular ejection fraction, both at rest and during rapid myocardial pacing (both p&lt;0.03), accompanied by increased perfusion to the most ischemic myocardial region at rest and during rapid pacing (both p&lt;0.03); reduced perivascular and interstitial fibrosis (both p &lt;0.03); and apoptosis (p=0.008). These changes were associated with increased activation of the endothelial-protective AMPK pathway (p=0.005), coupled with downstream increases in endothelial nitric oxide synthase (p=0.014).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study is the first to reveal the capacity of oral semaglutide to augment cardiac function in the chronically ischemic heart in a highly translational large animal model, likely through AMPK-mediated improvement in endothelial function and perfusion to the ischemic myocardium.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.08.15.608191","type":"posted-content","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:30:59Z","timestamp":1723854659000},"source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease"],"prefix":"10.64898","author":[{"given":"Christopher R.","family":"Stone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight D.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0393-9983","authenticated-orcid":false,"given":"Mark","family":"Broadwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghamsh","family":"Kanuparthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Woo","family":"Nho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keertana","family":"Yalamanchili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2758-8746","authenticated-orcid":false,"given":"Jad","family":"Hamze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2981-2638","authenticated-orcid":false,"given":"M. Ruhul","family":"Abid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-801X","authenticated-orcid":false,"given":"Frank W.","family":"Sellke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024082003351511000_2024.08.15.608191v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.005"},{"key":"2024082003351511000_2024.08.15.608191v1.2","unstructured":"WHO reveals leading causes of death and disability worldwide: 2000-2019 - PAHO\/WHO | Pan American Health Organization [Internet]. [cited 2024 Feb 13];Available from: https:\/\/www.paho.org\/en\/news\/9-12-2020-who-reveals-leading-causes-death-and-disability-worldwide-2000-2019"},{"key":"2024082003351511000_2024.08.15.608191v1.3","doi-asserted-by":"crossref","first-page":"101622","DOI":"10.1016\/j.cpcardiol.2023.101622","article-title":"Global Cardiovascular Diseases Death Rate Prediction","volume":"48","year":"2023","journal-title":"Current Problems in Cardiology"},{"key":"2024082003351511000_2024.08.15.608191v1.4","doi-asserted-by":"crossref","first-page":"e2034890","DOI":"10.1001\/jamanetworkopen.2020.34890","article-title":"Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019","volume":"4","year":"2021","journal-title":"JAMA Network Open"},{"key":"2024082003351511000_2024.08.15.608191v1.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.033126"},{"key":"2024082003351511000_2024.08.15.608191v1.6","doi-asserted-by":"publisher","DOI":"10.1210\/en.2018-00004"},{"key":"2024082003351511000_2024.08.15.608191v1.7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The Discovery and Development of Liraglutide and Semaglutide","volume":"10","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024082003351511000_2024.08.15.608191v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.07.008"},{"key":"2024082003351511000_2024.08.15.608191v1.9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","year":"2021","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2024082003351511000_2024.08.15.608191v1.10","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"2024082003351511000_2024.08.15.608191v1.11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The Cardiovascular Biology of Glucagon-like Peptide-1","volume":"24","year":"2016","journal-title":"Cell Metabolism"},{"key":"2024082003351511000_2024.08.15.608191v1.12","doi-asserted-by":"crossref","first-page":"e010321","DOI":"10.1161\/JAHA.118.010321","article-title":"GLP-1 Is a Coronary Artery Vasodilator in Humans","volume":"7","year":"2018","journal-title":"Journal of the American Heart Association"},{"key":"2024082003351511000_2024.08.15.608191v1.13","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0976"},{"key":"2024082003351511000_2024.08.15.608191v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.033"},{"key":"2024082003351511000_2024.08.15.608191v1.15","doi-asserted-by":"crossref","first-page":"e0130894","DOI":"10.1371\/journal.pone.0130894","article-title":"Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart","volume":"10","year":"2015","journal-title":"PLOS ONE"},{"key":"2024082003351511000_2024.08.15.608191v1.16","first-page":"292","article-title":"Pre-Treatment With Glucagon-Like Peptide-1 Protects Against Ischemic Left Ventricular Dysfunction and Stunning Without a Detected Difference in Myocardial Substrate Utilization","volume":"8","year":"2015","journal-title":"JACC: Cardiovascular Interventions"},{"key":"2024082003351511000_2024.08.15.608191v1.17","doi-asserted-by":"publisher","DOI":"10.2337\/db16-1206"},{"key":"2024082003351511000_2024.08.15.608191v1.18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2261-9-31","article-title":"Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model","volume":"9","year":"2009","journal-title":"BMC Cardiovascular Disorders"},{"key":"2024082003351511000_2024.08.15.608191v1.19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/14017431.2016.1197417","article-title":"Effects of liraglutide and ischemic postconditioning on myocardial salvage after I\/R injury in pigs*","volume":"51","year":"2017","journal-title":"Scandinavian Cardiovascular Journal"},{"key":"2024082003351511000_2024.08.15.608191v1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"2024082003351511000_2024.08.15.608191v1.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"2024082003351511000_2024.08.15.608191v1.22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","year":"2018","journal-title":"The Lancet"},{"key":"2024082003351511000_2024.08.15.608191v1.23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","year":"2019","journal-title":"The Lancet"},{"key":"2024082003351511000_2024.08.15.608191v1.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269"},{"key":"2024082003351511000_2024.08.15.608191v1.25","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective Effects of Exenatide in Patients With ST-Segment\u2013Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Arteriosclerosis","volume":"33","year":"2013","journal-title":"Thrombosis, and Vascular Biology"},{"key":"2024082003351511000_2024.08.15.608191v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.07.014"},{"key":"2024082003351511000_2024.08.15.608191v1.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q642"},{"key":"2024082003351511000_2024.08.15.608191v1.28","first-page":"69","article-title":"Ameroid constriction of the proximal left circumflex coronary artery in swine. A model of limited coronary collateral circulation","volume":"1","year":"1987","journal-title":"Am J Cardiovasc Pathol"},{"key":"2024082003351511000_2024.08.15.608191v1.29","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200102000-00010"},{"key":"2024082003351511000_2024.08.15.608191v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(99)00331-4"},{"key":"2024082003351511000_2024.08.15.608191v1.31","doi-asserted-by":"crossref","first-page":"H108","DOI":"10.1152\/ajpheart.2001.280.1.H108","article-title":"Stable labeled microspheres to measure perfusion: validation of a neutron activation assay technique","volume":"280","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024082003351511000_2024.08.15.608191v1.32","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00465.2002"},{"key":"2024082003351511000_2024.08.15.608191v1.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"2024082003351511000_2024.08.15.608191v1.34","unstructured":"Hiremath G , Batlivala S , Callahan R , Thatte N , Rockefeller T , Nawaytou H , Reddy SV , Hussain T , Chabiniok R , Butts R , et al. Clinical Applications of Pressure-Volume Assessment in Congenital Heart Disease. Journal of the Society for Cardiovascular Angiography & Interventions [Internet]. 2023 [cited 2023 Dec 28];2. Available from: https:\/\/www.jscai.org\/article\/S2772-9303(23)00026-1\/fulltext"},{"key":"2024082003351511000_2024.08.15.608191v1.35","doi-asserted-by":"crossref","first-page":"e028623","DOI":"10.1161\/JAHA.122.028623","article-title":"Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia","volume":"12","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2024082003351511000_2024.08.15.608191v1.36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","article-title":"A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans","volume":"34","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2024082003351511000_2024.08.15.608191v1.37","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12133","article-title":"Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes","volume":"15","year":"2013","journal-title":"Obesity and Metabolism"},{"key":"2024082003351511000_2024.08.15.608191v1.38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.091215"},{"key":"2024082003351511000_2024.08.15.608191v1.39","doi-asserted-by":"crossref","first-page":"113236","DOI":"10.1016\/j.biopha.2022.113236","article-title":"Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases","volume":"152","year":"2022","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2024082003351511000_2024.08.15.608191v1.40","unstructured":"Science\u2019s 2023 Breakthrough of the Year: Weight loss drugs with a real shot at fighting obesity [Internet]. [cited 2024 May 30];Available from: https:\/\/www.science.org\/content\/article\/breakthrough-of-the-year-2023"},{"key":"2024082003351511000_2024.08.15.608191v1.41","unstructured":"The Year of Ozempic | The New Yorker [Internet]. [cited 2024 May 30];Available from: https:\/\/www.newyorker.com\/culture\/2023-in-review\/the-year-of-ozempic"},{"key":"2024082003351511000_2024.08.15.608191v1.42","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s Disease","volume":"390","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"2024082003351511000_2024.08.15.608191v1.43","doi-asserted-by":"crossref","first-page":"22063","DOI":"10.1038\/s41598-021-01663-y","article-title":"A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1- RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)","volume":"11","year":"2021","journal-title":"Sci Rep"},{"key":"2024082003351511000_2024.08.15.608191v1.44","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","year":"2023","journal-title":"N Engl J Med"},{"key":"2024082003351511000_2024.08.15.608191v1.45","doi-asserted-by":"crossref","unstructured":"Perkovic Vlado , Tuttle Katherine R. , Rossing Peter , Mahaffey Kenneth W. , Mann Johannes F.E. , Bakris George , Baeres Florian M.M. , Idorn Thomas , Bosch-Traberg Heidrun , Lausvig Nanna Leonora , et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine [Internet]. [cited 2024 May 30];0. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2403347","DOI":"10.1056\/NEJMoa2403347"},{"key":"2024082003351511000_2024.08.15.608191v1.46","doi-asserted-by":"crossref","unstructured":"Eid O , Eid R , Styliou T , Diakonikolaou S , Christou V , Karataraki F , Abdelrahman R , Moutiris J . Prevalence and impact of high BMI in CAD patients. European Journal of Preventive Cardiology. 2022;29:zwac056.179.","DOI":"10.1093\/eurjpc\/zwac056.179"},{"key":"2024082003351511000_2024.08.15.608191v1.47","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp19X702725"},{"key":"2024082003351511000_2024.08.15.608191v1.48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jss.2009.03.024","article-title":"Correlation of Ischemic Area and Coronary Flow With Ameroid Size in a Porcine Model","volume":"164","year":"2010","journal-title":"Journal of Surgical Research"},{"key":"2024082003351511000_2024.08.15.608191v1.49","doi-asserted-by":"crossref","first-page":"H930","DOI":"10.1152\/ajpheart.1998.274.3.H930","article-title":"Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia","volume":"274","year":"1998","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"key":"2024082003351511000_2024.08.15.608191v1.50","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00395-014-0426-9","article-title":"GLUCAGON LIKE PEPTIDE-1(7\u201336) BUT NOT (9\u201336) AUGMENTS CARDIAC OUTPUT DURING MYOCARDIAL ISCHEMIA VIA AFRANK-STARLING MECHANISM","volume":"109","year":"2014","journal-title":"Basic Res Cardiol"},{"key":"2024082003351511000_2024.08.15.608191v1.51","doi-asserted-by":"crossref","first-page":"H1139","DOI":"10.1152\/ajpheart.00705.2019","article-title":"Hemodynamic assessment of diastolic function for experimental models","volume":"318","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2024082003351511000_2024.08.15.608191v1.52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.15420\/cfr.2019.11.2","article-title":"Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice","volume":"5","year":"2019","journal-title":"Card Fail Rev"},{"key":"2024082003351511000_2024.08.15.608191v1.53","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0391"},{"key":"2024082003351511000_2024.08.15.608191v1.54","unstructured":"Cardiovascular Actions of Incretin-Based Therapies | Circulation Research [Internet]. [cited 2024 May 31];Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCRESAHA.114.301958?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed"},{"key":"2024082003351511000_2024.08.15.608191v1.55","first-page":"432","article-title":"A Comparative Anatomic and Physiologic Overview of the Porcine Heart","volume":"53","year":"2014","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"2024082003351511000_2024.08.15.608191v1.56","first-page":"549","article-title":"The pathogenesis of cardiac fibrosis","volume":"71","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"2024082003351511000_2024.08.15.608191v1.57","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3390\/ijerph18041773","article-title":"Metabolic Syndrome and Coronary Artery Disease Risk: A Meta-Analysis of Observational Studies","volume":"18","year":"2021","journal-title":"Int J Environ Res Public Health"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.08.15.608191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:52:39Z","timestamp":1768459959000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.08.15.608191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":57,"URL":"https:\/\/doi.org\/10.1101\/2024.08.15.608191","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1161\/ATVBAHA.124.321850","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,8,16]]},"subtype":"preprint"}}